Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Golumba-Nagy V. et al.
  • Year: 2017
  • Journal: Hum Gene Ther Methods 28 no.6
  • Applications: in vitro / DNA / PEIpro
  • Cell type: HEK-293T
    Description: Human embryonic kidney Fibroblast
    Known as: HEK293T, 293T

Method

Dish/vessel: 10 cm dish. Growth medium: DMEM 10 % HI FCS. Seeding: 3x10^6 per dish the day before. DNA : 30 µg. Reagent Amount: 30 µL. Ratio: 1:1. Complexation medium: DMEM. Complexation time: 15 min RT.

Abstract

Redirected T cells genetically modified with a chimeric antigen receptor (CAR) induced spectacular remissions of so far refractory leukemia/lymphoma in early phase trials attracting interest to use CAR T cells in a variety of other applications including solid cancer and non-malignant diseases. However, extensive pre-clinical explorations demand highly effective and robust procedures for the genetic modification of blood T cells; the same applies for engineering with a recombinant T cell receptor (TCR). We present laboratory procedures in a step-by-step protocol to engineer human and mouse T cells with a CAR by retro- or lentiviral transduction for further pre-clinical testing.

Go to